LONDON, UNITED KINGDOM--(Marketwired - Jan 13, 2016) - Plandaí Biotechnology, Inc. (
TNT performed an in-house study that began in March of 2015 called "TNT: Strong to the Core," in which 12 subjects were given four TNT capsules per day and asked to follow a moderate 3x a week exercise regimen and consume a normal calorie diet (2,000 a day for men, 1,500 for women). The results as reported by TNT were astounding with each of the 12 subjects losing significant weight and reducing body fat (2-3 lbs. average per week). One such subject lost a massive total of 70 lbs. (32kg) over the course of 18 weeks. While acknowledging that this was not a full clinical trial, TNT believes the results are nevertheless encouraging and merited the large-scale release of the product to the market.
Callum Cottrell-Duffield, Vice President of Sales and Marketing for Plandaí Biotechnology, stated, "We at Plandaí are more than thrilled to be working with TNT Supplements on their TNT product, a company that prides itself of using only the highest quality ingredients that generate real results. The reported weight and fat loss from using TNT are phenomenal, and we consider this to be a truly remarkable breakthrough for people around the world who suffer from weight-related health issues."
TNT Supplements added the following statement, "Phytofare® made a huge impact in our TNT Fat Burner, and we are thrilled to have access to such an incredible product that helps us make TNT the best possible for our customers. We understand that not everyone is capable of an intense workout regimen and, frankly, no one enjoys drastic calorie restriction diets. The beauty of the Phytofare®-enhanced TNT Fat Burner is that tremendous results can be obtained from a moderate exercise program and a reasonable, healthy diet. We look forward to expanding sales of TNT outside the UK and into Europe and the US in the coming months."
For more information about TNT Fat Burner, to read the study details, or order product, visit the company website: http://www.tntfatburner.co.uk/.
About Plandaí Biotechnology, Inc.
Plandaí Biotechnology, Inc. and its subsidiaries develop highly phyto-available™ extracts. Plandaí Biotechnology controls every aspect of the process, from growing the raw materials on its farms in South Africa, to producing its proprietary Phytofare® extracts in-house, allowing the Company to guarantee the continuity of supply as well as quality control throughout the entire process. Targeted industries for the Company's products include beverage, cosmeceutical, wellness, nutraceutical, anti-aging, and pharmaceutical. For more information, please visit http://www.plandaibiotech.com.
Safe Harbor Statement
This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance or guarantee that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to: adverse economic conditions, competition, adverse federal, state and local government regulation, international governmental regulation, inadequate capital, inability to carry out research, development and commercialization plans, loss or retirement of key executives and other specific risks. To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made. Readers are advised to review our filings with the Securities and Exchange Commission that can be accessed over the Internet at the SEC's website located at http://www.sec.gov.